Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric Cancer

Trial details

Who runs it

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Trial code

NCT05149807

Record updated

2025. augusztus 20.

Original description

This is a multi-center phase II/III clinical study consisting of two stages: Stage I is a single-arm open-label phase II study to preliminarily explore the efficacy and safety of SHR-1701 plus S-1 and oxaliplatin mainly by the endpoint of pCR rate.Read full original descriptionShow less

A Randomized, Double-Blind, Multi-Center Phase II/III Clinical Study of PD-L1 Antibody/TGF-βRII (SHR-1701) Plus Tegafur Gimeracil Oteracil Potassium and Oxaliplatin Versus Placebo Plus Tegafur Gimeracil Oteracil Potassium and Oxaliplatin as Perioperative Treatment in Subjects With Resectable Gastric Cancer or Gastroesophageal Junction Cancer

This is a multi-center phase II/III clinical study consisting of two stages: Stage I is a single-arm open-label phase II study to preliminarily explore the efficacy and safety of SHR-1701 plus S-1 and oxaliplatin mainly by the endpoint of pCR rate.

Stage II is a randomized, double-blind, multi-center phase III study of SHR-1701 plus S-1 and oxaliplatin versus placebo plus S-1 and oxaliplatin as perioperative treatment in subjects with resectable GC or GEJC. A total of 846 treatment naïve subjects will be enrolled, and primary endpoint of this stage is Independent Review Committee (IRC)-assessed EFS.

Inclusion: Pathologically diagnosed with GC or GEJC, histologically confirmed to be adenocarcinoma, and have no previous anti-tumor treatments for GC or GEJC; Aged 18 or above, male or female; Be suitable for (investigator's assessment) and planning to undergo neoadjuvant therapy + radical surgery with curative intent before entering into the study; locally advanced Gastric Cancer or Gastroesophageal Junction Cancer confirmed by investigator; Be able to provide tumor tissue blocks; Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1; Life expectancy of ≥ 6 months; Have adequate organ and bone marrow functions; Women without childbearing potential refer to post-menopausal women, or women who underwent bilateral oophorectomy with medical records. Male subjects and female subjects of childbearing potential must agree to take a medically approved contraceptive measure (refer to Appendix 4) during the study, within 3 months after the last dose of investigational product (SHR-1701), and within 9 months after the last dose of chemotherapy agents (S-1 and oxaliplatin); have a negative serum pregnancy test result within 3 days prior to the start of study treatment and not be breastfeeding; Subjects must agree and have signed the informed consent form, be willing and able to follow the scheduled visits, study treatment, laboratory tests, and other study procedures.

Exclusion: Have unresectable factors, including unresectable tumors or contraindications to surgery or refusal of surgery; Have more than 20% weight loss within 2 months prior to enrollment or randomization; Have previously received some treatments or medications including anti-tumor treatments; Diagnosed with other malignant tumors within 5 years prior to enrollment; Have clinically significant bleeding symptoms or clear bleeding tendency within 3 months prior to enrollment or randomization; have gastrointestinal perforation and/or gastrointestinal fistula within 6 months prior to enrollment or randomization; have arterial/venous thrombotic events within 6 months prior to enrollment or randomization; Have major vascular disease within 6 months prior to enrollment or randomization; Have intestinal obstruction and/or clinical signs or symptoms of gastrointestinal obstruction within 6 months prior to enrollment or randomization; Have received systemic antibiotics for ≥ 7 days within 4 weeks prior to enrollment or randomization, or have unexplained fever > 38.5 °C during screening or before the first dose; Have been screened for other clinical studies but failed the screening because PD-L1 expression did not meet the inclusion criteria or met the exclusion criteria; have participated in clinical studies of any other drugs, less than 4 weeks or 5 half-lives of the drug between the last dose of these study treatments and enrollment/randomization for this study (whichever is longer); Have known squamous cell carcinoma, undifferentiated carcinoma, or other histological types of gastric cancer, or adenocarcinoma mixed with gastric cancer of other histological types; Have any active, known, or suspected autoimmune disease; Have interstitial lung disease, non-infectious pneumonitis, or uncontrolled systemic disease; Have known allergies to the study drug or their excipients; have severe allergic reactions to other monoclonal antibodies; Have HIV infection or known AIDS, active untreated hepatitis or co-infection with hepatitis B and C; Have uncontrolled cardiac symptoms or disease:; Have known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation; Have a known history of psychotropic substance abuse or drug abuse; Have other severe physical or psychiatric disorders or laboratory abnormalities, which may increase the risk of participation in this study or interfere with the study results, or deemed unsuitable by the investigator; Have severe, unhealed, or dehisced wounds and active ulcers or untreated fractures.

ClinicalTrials.gov NCT05149807